Publications

Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Abstract

There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.

Type Journal
ISBN 1879-0461 (Electronic) 1040-8428 (Linking)
Authors Nagrial, A. M.; Chin, V. T.; Sjoquist, K. M.; Pajic, M.; Horvath, L. G.; Biankin, A. V.; Yip, D.;
Responsible Garvan Author
Publisher Name CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Published Date 2015-12-01 00:00:00
Published Volume 96
Published Issue 3
Published Pages 483-97
Status Published in-print
URL link to publisher's version http://www.ncbi.nlm.nih.gov/pubmed/26481952
OpenAccess link to author's accepted manuscript version https://publications.gimr.garvan.org.au/open-access/13240